SCHEMBL190307

SCHEMBL190307

CC(C)(C)OC(=O)N1CCNC(=O)C1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.59
TSHR P16473 1/20 0.48
KMT2A Q03164 1/20 0.47
POLB P06746 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
USP2 O75604 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
ESR2 Q92731 1/20 0.43
NR1H2 P55055 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
HSP90AA1 P07900 1/20 0.40
ADORA1 P30542 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL29233432 0.94 MAPK1 (0.54) MAPK1TSHRKMT2APOLBTDP1
SCHEMBL326544 0.90 MAPK1 (0.50) MAPK1TSHRKMT2APOLBTDP1
SCHEMBL327562 0.85 MAPK1 (0.51) MAPK1KMT2APOLBSMN1; SMN2USP2
SCHEMBL2028229 0.84 MAPK1 (0.45) MAPK1TSHRKMT2APOLBTDP1
SCHEMBL13812240 0.84 CHRM2 (0.51) MAPK1TSHRKMT2APOLBTDP1
SCHEMBL14686817 0.83 MAPT (0.44) MAPK1SMN1; SMN2USP2ESR2NR1H2
SCHEMBL7502314 0.83 MAPK1 (0.56) MAPK1KMT2ASMN1; SMN2L3MBTL1GAA
SCHEMBL13082631 0.82 MAPK1 (0.62) MAPK1KMT2APOLBSMN1; SMN2USP2
SCHEMBL3524396 0.82 MAPK1 (0.58) MAPK1POLBSMN1; SMN2USP2ESR2
SCHEMBL16853010 0.82 MAPK1 (0.58) MAPK1POLBSMN1; SMN2USP2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117964561-A HIV-1 capsid inhibitor intermediate and synthesis method thereof 常熟泓德生物科技有限公司 2024-05-03 CN claimed
CN-117384240-A HIV-1 capsid protein degradation agent based on hydrophobic tag technology and preparation method and application thereof 山东大学 2024-01-12 CN claimed
CN-117362387-A Benzenesulfonamide piperazinone glycine derivative as well as preparation method and application thereof 山东大学 2024-01-09 CN claimed
CN-109824756-B Phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and preparation method and application thereof 山东大学 2022-03-22 CN claimed
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 CN claimed
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2026-05-28 US disclosed
EP-4747245-A1 PHARMACEUTICAL COMPOUNDS Almac Discovery Limited (GB) 2026-05-27 EP disclosed
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 US disclosed
EP-4737455-A1 COMPOUND CONTAINING MULTI-FUSED RING STRUCTURE Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2026-05-06 EP disclosed
US-12606533-B2 3-phenylpropylamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-04-21 US disclosed
WO-1996010022-A1 AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS ZENECA LIMITED (GB) 1996-04-04 WO disclosed
US-4771046-A ANTIBIOTICS SANKYO COMPANY, LIMITED (JP) 1988-09-13 US disclosed
EP-0202048-A1 Carbapenem derivatives, their preparation, and pharmaceutical compositions containing them SANKYO COMPANY LIMITED (JP) 1986-11-20 EP disclosed
US-4483988-A Substituted derivatives of 4-t-alkoxycarbonyl-piperazin-2-ones RICHARDSON MERRELL INC. (US) 1984-11-20 US disclosed
US-4435571-A 5-(Substituted benzyl)-6-oxo-2-piperazine carboxylic acids and esters RICHARDSON MERRELL INC. (US) 1984-03-06 US disclosed
US-4341698-A Enkaphalin derivatives RICHARDSON-MERRELL INC. (US) 1982-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146042-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES CDK9, CDK6, CDK7 MAPK1 118/4885TSHR 2140/4885KMT2A 915/4885
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 MAPK1 2997/4885TSHR 70/4885KMT2A 1231/4885
US-12606533-B2 3-phenylpropylamine derivative SF3A1, SF1, HTR1D MAPK1 1850/4885TSHR 1117/4885KMT2A 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.